Driehaus Capital Management LLC acquired a new stake in Design Therapeutics, Inc. (NASDAQ:DSGN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 776,082 shares of the company's stock, valued at approximately $4,788,000. Driehaus Capital Management LLC owned 1.37% of Design Therapeutics at the end of the most recent quarter.
Several other large investors have also modified their holdings of the company. American Century Companies Inc. raised its stake in shares of Design Therapeutics by 19.9% during the fourth quarter. American Century Companies Inc. now owns 39,115 shares of the company's stock worth $241,000 after purchasing an additional 6,481 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Design Therapeutics by 186.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 40,687 shares of the company's stock valued at $219,000 after buying an additional 26,503 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Design Therapeutics by 2.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 264,675 shares of the company's stock valued at $1,633,000 after buying an additional 7,243 shares during the period. Barclays PLC increased its stake in Design Therapeutics by 34.2% in the 3rd quarter. Barclays PLC now owns 96,635 shares of the company's stock valued at $520,000 after buying an additional 24,602 shares during the period. Finally, Geode Capital Management LLC increased its stake in Design Therapeutics by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 761,640 shares of the company's stock valued at $4,700,000 after buying an additional 3,090 shares during the period. 56.64% of the stock is owned by institutional investors and hedge funds.
Design Therapeutics Stock Performance
DSGN traded up $0.07 during trading on Thursday, hitting $3.29. The stock had a trading volume of 20,125 shares, compared to its average volume of 187,056. Design Therapeutics, Inc. has a twelve month low of $2.60 and a twelve month high of $7.77. The company's 50-day moving average price is $3.95 and its 200 day moving average price is $4.92. The firm has a market capitalization of $186.77 million, a P/E ratio of -3.88 and a beta of 1.77.
Design Therapeutics (NASDAQ:DSGN - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.03). As a group, equities analysts expect that Design Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.
Design Therapeutics Profile
(
Free Report)
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.
Featured Stories
Before you consider Design Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Design Therapeutics wasn't on the list.
While Design Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
